Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland
Prognostic factors and long-term treatment response of interferon β-1a s.c tiw has not been studied in a real-life clinical cohort in Finland. The aim of the paper was to evaluate long-term treatment response, prognostic clinical factors and adherence among interferon β-1a s.c tiw treated patients i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-11-01
|
| Series: | Neurology International |
| Subjects: | |
| Online Access: | https://www.pagepress.org/journals/index.php/ni/article/view/8177 |
| _version_ | 1797936648570273792 |
|---|---|
| author | Elina Järvinen Annukka Murtonen Melina Tervomaa Marja-Liisa Sumelahti |
| author_facet | Elina Järvinen Annukka Murtonen Melina Tervomaa Marja-Liisa Sumelahti |
| author_sort | Elina Järvinen |
| collection | DOAJ |
| description | Prognostic factors and long-term treatment response of interferon β-1a s.c tiw has not been studied in a real-life clinical cohort in Finland. The aim of the paper was to evaluate long-term treatment response, prognostic clinical factors and adherence among interferon β-1a s.c tiw treated patients in Finland. A retrospective review of medical records was performed. Confirmed relapsing multiple sclerosis patients treated with interferon β-1a s.c tiw 22μg or 44μg as their first treatment, from 1996 to 2010 in Western Finland, were included. Longitudinal generalized linear regression models were applied to assess risk of disability progression, using Expanded Disability Status Scale (EDSS), during the treatment period. Odd’s ratios with 95% confidence intervals (95% CI) were calculated for risk factors: gender, age at diagnosis, treatment delay, dose, baseline EDSS and EDSS change in one year. Kaplan-Meier was applied to study median time to discontinuation. Mean duration of treatment in 293 cases was 2.9 years (min 0.04, max 13.5). EDSS increase vs. no increase in one-year carried a significant risk for long-term disability progression (1.20, 1.08-1.33). Older age, defined by a 10-year increase in age at diagnosis (1.43, 1.07 -1.91) and one-year delay to treatment start showed an increased risk for disability progression (1.05, 0.99-1.11), but gender (0.66, 0.38-1.15) or initial dose (1.00, 0.45-2.25) showed no risk. Treatment was stopped in 37% due to disease activation at median of 1.7 years, and in 25% due to side effects at 9.3 months. Our results show that young age, a short delay to treatment start and slower disability progression were identified as factors for better outcome among cases with interferon β-1a s.c tiw as their first disease modifying treatment. |
| first_indexed | 2024-04-10T18:32:35Z |
| format | Article |
| id | doaj.art-ea597dbfac89446383b5d2c661494944 |
| institution | Directory Open Access Journal |
| issn | 2035-8385 2035-8377 |
| language | English |
| last_indexed | 2024-04-10T18:32:35Z |
| publishDate | 2019-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Neurology International |
| spelling | doaj.art-ea597dbfac89446383b5d2c6614949442023-02-02T03:11:39ZengMDPI AGNeurology International2035-83852035-83772019-11-0111410.4081/ni.2019.8177Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in FinlandElina Järvinen0Annukka Murtonen1Melina Tervomaa2Marja-Liisa Sumelahti3Merck Finland, Espoo; Department of Medicine, University of HelsinkiFaculty of Medicine and Life Sciences, University of TampereStatFinn, EspooMerck Finland, Espoo; Department of Medicine, University of HelsinkiPrognostic factors and long-term treatment response of interferon β-1a s.c tiw has not been studied in a real-life clinical cohort in Finland. The aim of the paper was to evaluate long-term treatment response, prognostic clinical factors and adherence among interferon β-1a s.c tiw treated patients in Finland. A retrospective review of medical records was performed. Confirmed relapsing multiple sclerosis patients treated with interferon β-1a s.c tiw 22μg or 44μg as their first treatment, from 1996 to 2010 in Western Finland, were included. Longitudinal generalized linear regression models were applied to assess risk of disability progression, using Expanded Disability Status Scale (EDSS), during the treatment period. Odd’s ratios with 95% confidence intervals (95% CI) were calculated for risk factors: gender, age at diagnosis, treatment delay, dose, baseline EDSS and EDSS change in one year. Kaplan-Meier was applied to study median time to discontinuation. Mean duration of treatment in 293 cases was 2.9 years (min 0.04, max 13.5). EDSS increase vs. no increase in one-year carried a significant risk for long-term disability progression (1.20, 1.08-1.33). Older age, defined by a 10-year increase in age at diagnosis (1.43, 1.07 -1.91) and one-year delay to treatment start showed an increased risk for disability progression (1.05, 0.99-1.11), but gender (0.66, 0.38-1.15) or initial dose (1.00, 0.45-2.25) showed no risk. Treatment was stopped in 37% due to disease activation at median of 1.7 years, and in 25% due to side effects at 9.3 months. Our results show that young age, a short delay to treatment start and slower disability progression were identified as factors for better outcome among cases with interferon β-1a s.c tiw as their first disease modifying treatment.https://www.pagepress.org/journals/index.php/ni/article/view/8177Multiple sclerosis, Interferon β-1a s.c tiw, Disability progression, EDSS |
| spellingShingle | Elina Järvinen Annukka Murtonen Melina Tervomaa Marja-Liisa Sumelahti Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland Neurology International Multiple sclerosis, Interferon β-1a s.c tiw, Disability progression, EDSS |
| title | Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland |
| title_full | Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland |
| title_fullStr | Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland |
| title_full_unstemmed | Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland |
| title_short | Interferon β-1a subcutaneously 3 times/week clinical outcome in relapsing multiple sclerosis in Finland |
| title_sort | interferon β 1a subcutaneously 3 times week clinical outcome in relapsing multiple sclerosis in finland |
| topic | Multiple sclerosis, Interferon β-1a s.c tiw, Disability progression, EDSS |
| url | https://www.pagepress.org/journals/index.php/ni/article/view/8177 |
| work_keys_str_mv | AT elinajarvinen interferonb1asubcutaneously3timesweekclinicaloutcomeinrelapsingmultiplesclerosisinfinland AT annukkamurtonen interferonb1asubcutaneously3timesweekclinicaloutcomeinrelapsingmultiplesclerosisinfinland AT melinatervomaa interferonb1asubcutaneously3timesweekclinicaloutcomeinrelapsingmultiplesclerosisinfinland AT marjaliisasumelahti interferonb1asubcutaneously3timesweekclinicaloutcomeinrelapsingmultiplesclerosisinfinland |